Global Health

THE LANCET byMichel Van Herp, Hilde Declerck and Tom Decroo June 13, 2015

.. the efficacy of candidate Ebola vaccines for primary prevention has not been proven.² Furthermore, in communities in which Ebola transmission might be ongoing, an important question is: how will such a vaccination be perceived if a vaccinated person develops Ebola? Such a scenario is possible in people who contract Ebola virus before vaccination. If a person is infected with Ebola virus before vaccination, the vaccine might have a post-exposure prophylactic effect. However, how effective this prophylaxis might be is unknown.² Moreover, if someone is infected more than 48 h before vaccination, the post-exposure prophylactic effect is likely to be insufficient, leading to possible development of Ebola after vaccination. This scenario is likely to result in serious issues relating to community trust and acceptance of an Ebola vaccine.³ How to exclude Ebola among people presenting with post-vaccination fever is also an issue.²

PLOS by Arlene C. Chua,Jane Cunningham,Francis Moussy, Mark D. Perkins,and Pierre Formenty      June 11 2015

 ...Since the identification of Ebola in Guinea in March 2013, rapid deployment of international mobile laboratories through WHO networks—Global Outbreak Alert and Response Network (GOARN) [2] and Emerging and Dangerous Pathogens Laboratory Network (EDPLN) [3]—has been vital to outbreak control operations. Deployable laboratories from multiple international organizations have been established near Ebola treatment centers (ETC) in Guinea, Liberia, and Sierra Leone....

However, several technical and social factors conspire to delay diagnosis, starting with weak surveillance systems and slow patient access to centralized ETCs. While the mean processing time is 5 hours (time difference from when samples are received in the laboratory to when they are tested), there is a marked difference in the time from when the samples are collected from suspected patients to the time they are received by the laboratory

PUBLIC BROADCASTING CORP by Caleb Hellerman         June 11, 2015

The quest for an Ebola vaccine has been a journey filled with excruciating delays and mad dashes. The latest outbreak in West Africa caused governments and drug companies to jumpstart research that had languished back when the threat of Ebola wasn’t big enough to sustain a commercial market. (Prior to 2013, the virus had sickened fewer than 2,300 people in known history). Human safety trials of two vaccines began last summer — each being given to a small group of healthy volunteers. When no major side effects were apparent, health officials scrambled to launch larger tests in the countries that were most affected by Ebola.

A volunteer receives an Ebola vaccine in Sierra Leone. Thousands of these voluntary immunizations have been tested so far in the West African nation. Photo by Cameron Hickey.

Image: Congo Town, Freetown, Sierra Leone. Photo: Dylan Lowthian/UNDP

africa.undp.org - May 9th, 2015

United Nations Secretary-General Ban Ki-moon will host an International Ebola Recovery Conference in July to ensure that the affected countries receive the resources and support they need to overcome the wider socio-economic consequences of the ongoing Ebola outbreak.

The conference at United Nations Headquarters in New York on 10 July 2015 will take place in cooperation with the Governments of Guinea, Liberia and Sierra Leone, together with other partners. 

With numbers of Ebola cases have dropped, the affected countries still need the support of the international community to get to zero cases, stay there, and to move forward on the road to recovery.

(VIEW COMPLETE ARTICLE)